請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/26772
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 陳小梨(Show-Li Chen) | |
dc.contributor.author | Hung-Wei Chang | en |
dc.contributor.author | 張紘瑋 | zh_TW |
dc.date.accessioned | 2021-06-08T07:24:55Z | - |
dc.date.copyright | 2008-08-13 | |
dc.date.issued | 2008 | |
dc.date.submitted | 2008-07-17 | |
dc.identifier.citation | Alimirah F, Panchanathan R, Chen J, Zhang X, Ho SM, Choubey D. (2007). Expression of androgen receptor is negatively regulated by p53. Neoplasia. 9, 1152-9.
Almeida A, Muleris M, Dutrillaux B, Malfoy B. (1994). The insulin-like growth factor I receptor gene is the target for the 15q26 amplicon in breast cancer. Genes Chromosomes Cancer. 11, 63-65. Adnane J, Gaudray P, Dionne CA, Crumley G, Jaye M, Schlessinger J, Jeanteur P, Birnbaum D, Theillet C. (1991). BEK and FLG, two receptors to members of the FGF family, are amplified in subsets of human breast cancers. Oncogene. 6, 659-63. Aylon Y, Oren M. (2007). Living with p53, dying of p53. Cell. 130, 597-600. Berns EM, Foekens JA, van Staveren IL, van Putten WL, de Koning HY, Portengen H, Klijn JG. (1995). Oncogene amplification and prognosis in breast cancer: relationship with systemic treatment. Gene 159, 11-18. Beck BD, Park SJ, Lee YJ, Roman Y, Hromas RA, Lee SH. (2008). Human Pso4 is a metnase (SETMAR)-binding partner that regulates metnase function in DNA repair. J Biol Chem. 283, 9023-30 Bode AM, Dong Z. (2004). Post-translational modification of p53 in tumorigenesis. Nat Rev Cancer. 4, 793-805. Brummelkamp, T. R., Bernards, R., and Agami, R. (2002). A system for stable expression of short interfering RNAs in mammalian cells. Science 296, 550–553 Burkhard P, Stetefeld J, Strelkov SV. (2001). Coiled coils: a highly versatile protein folding motif. Trends Cell Biol. 11, 82-8. Review. Cavenee WK, Dryja TP, Phillips RA, Benedict WF, Godbout R, Gallie BL, Murphree AL, Strong LC, White RL. (1983). Expression of recessive alleles by chromosomal mechanisms in retinoblastoma. Nature 305, 779-784. Chen H, Lin RJ, Schiltz RL, Chakravarti D, Nash A, Nagy L, Privalsky ML, Nakatani Y, Evans RM. (1997). Nuclear receptor coactivator ACTR is a novel histone acetyltransferase and forms a multimeric activation complex with P/CAF and CBP/p300. Cell 90, 569-580. Cronauer MV, Schulz WA, Burchardt T, Ackermann R, Burchardt M. (2004). Inhibition of p53 function diminishes androgen receptor-mediated signaling in prostate cancer cell lines. Oncogene 23, 3541-3549. Culig Z, Hobisch A, Bartsch G, Klocker H. (2000). Expression and function of androgen receptor in carcinoma of the prostate. Microsc Res Tech. 51, 447-55 Culig Z, Klocker H, Bartsch G, Hobisch A. (2002).Androgen receptors in prostate cancer. Endocr Relat Cancer. 9, 155-70. Review Culig Z, Comuzzi B, Steiner H, Bartsch G, Hobisch A. (2004). Expression and function of androgen receptor coactivators in prostate cancer. J Steroid Biochem Mol Biol. 92, 265-71. Review. Delahay RM, Frankel G. (2002). Coiled-coil proteins associated with type III secretion systems: a versatile domain revisited. Mol Microbiol. 45, 905-16. Review. Eastham JA, Grafton W, Martin CM, Williams BJ. (2000). Suppression of primary tumor growth and the progression to metastasis with p53 adenovirus in human prostate cancer. J Urol. 164, 814-9. Edwards J, Bartlett JM. (2005). The androgen receptor and signal-transduction pathways in hormone-refractory prostate cancer. Part 1: Modifications to the androgen receptor. BJU Int. 95, 1320-6. Review Edwards J, Bartlett JM. (2005). The androgen receptor and signal-transduction pathways in hormone-refractory prostate cancer. Part 2: Androgen-receptor cofactors and bypass pathways. BJU Int. 95, 1327-35. Review. el-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, Lin D, Mercer WE, Kinzler KW, Vogelstein B. (1993). WAF1, a potential mediator of p53 tumor suppression. Cell. 75, 817-25. el-Deiry WS. (1998). p21/p53, cellular growth control and genomic integrity. Curr Top Microbiol Immunol. 227, 121-37. Erster S, Moll UM. (2005). Stress-induced p53 runs a transcription-independent death program. Biochem Biophys Res Commun. 331, 843-50. Review. Evans RM. (1988). The steroid and thyroid hormone receptor superfamily.Science 240, 889-895. Fingerman IM, Briggs SD. (2004). p53-mediated transcriptional activation: from test tube to cell. Cell. 117, 690-1. Frasor J, Danes JM, Komm B, Chang KCN, Lyttle R, Katzenellenbogen BS. (2003). Fujimoto N, Yeh S, Kang HY, Inui S, Chang HC, Mizokami A, Chang C. (1999). Cloning and characterization of androgen receptor coactivator, ARA55, in human prostate. J Biol Chem 274, 8316-8321. Profiling of estrogen up-and downregulated gene expression in human breast cancers cells: insights into gene networks and pathways underlying estrogenic control of proliferation and cell phenotype. Endocrinology 144, 4562–4574. Gordan A. N., Fleagle J. T., Guthrie D., Parkin D. E., Gore M. E., Lacave A. J. (2001). Recurrent epithelial ovarian carcinoma: a randomized phase Ⅲ study of pegylated liposomal doxorubicin versus topotecan. J. Clin. Oncol. 19, 3312-3322 Gaudray P, Szepetowski P, Escot C, Birnbaum D, Theillet C. (1992). DNA amplification at 11q13 in human cancer: from complexity to perplexity. Mutat Res 276, 317-328. Genuardi M, Tsihira H, Anderson DE, Saunders GF. (1989). Distal deletion of chromosome Ip in ductal carcinoma of the breast. Am J Hum Genet 45, 73-82. Giancotti V. (2006). Breast cancer markers. Cancer Lett 243, 145-159. Gillett C, Fantl V, Smith R, Fisher C, Bartek J, Dickson C, Barnes D, Peters G.. (1994). Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining. Cancer Res. 54, 1812-7. Goss PE. (2004). The rise and current status of aromatase inhibitors in breast cancer treatment, in abstracts of San antonio breast cancer symposium. Breast Cancer Res Treat 88, S1. Hannon GJ, Rossi JJ. (2004). Unlocking the potential of the human genome with RNA interference. Science 434, 371-378 Harper JW, Elledge SJ, Keyomarsi K, Dynlacht B, Tsai LH, Zhang P, Dobrowolski S, Bai C, Connell-Crowley L, Swindell E, et al. (1995). Inhibition of cyclin-dependent kinases by p21. Mol Biol Cell. 6, 387-400 He B, Kemppainen JA, Voegel JJ, Gronemeyer H, Wilson EM. (1999). Activation function 2 in the human androgen receptor ligand binding domain mediates interdomain communication with the NH(2)-terminal domain. J Biol Chem. 274, 37219-25. He B, Kemppainen JA, Wilson EM. (2000). FXXLF and WXXLF sequences mediate the NH2-terminal interaction with the ligand binding domain of the androgen receptor. J Biol Chem. 275, 22986-94. Hegde R, Srinivasula SM, Ahmad M, Fernandes-Alnemri T, Alnemri ES. (1998). Blk, a BH3-containing mouse protein that interacts with Bcl-2 and Bcl-xL, is a potent death agonist. J. Biol. Chem. 273, 7783–7786. Heinlein CA, Chang C. (2002). Androgen receptor (AR) coregulators: an overview. Endocr Rev. 23, 175-200. Review. Huang J, Sengupta R, Espejo AB, Lee MG, Dorsey JA, Richter M, Opravil S, Shiekhattar R, Bedford MT, Jenuwein T, Berger SL. (2007). p53 is regulated by the lysine demethylase LSD1. Nature. 449, 105-8. Jenster G, Spencer TE, Burcin MM, Tsai SY, Tsai MJ, O'Malley BW. (1997). Steroid receptor induction of gene transcription: a two-step model. Proc Natl Acad Sci USA 94, 7879-7884. Jenster G. (1999). The role of the androgen receptor in the development and progression of prostate cancer. Semin Oncol. 26, 407-21 Jiang, Z.H., Zhang, W.J., Rao, Y., and Wu, J.Y. (1998). Regulation of Ich-1 pre-mRNA alternative splicing and apoptosis by mammalian splicing factors. Proc. Natl. Acad. Sci. 95, 9155–9160. Klein C, Vassilev LT. (2004). Targeting the p53-MDM2 interaction to treat cancer. Br J Cancer. 91, 1415-9 Kuiper GG, Enmark E, Pelto-Huikko M, Nilsson S, Gustafsson JA. (1996). Cloning of a novel receptor expressed in rat prostate and ovary. Proc Natl Acad Sci USA 93, 5925-5930. Lee S, Ha S, Chung M, Kim Y, Choi Y. (2002). Mouse DAM1 regulates pro-apoptotic activity of BLK in mammary epithelial cells. Cancer Lett 188, 121-126. Lee JH, Takahashi T, Yasuhara N, Inazawa J, Kamada S, Tsujimoto Y. (1999). Bis, a Bcl-2-binding protein that synergizes with Bcl-2 in preventing cell death. Oncogene. 18, 6183-90 Levav-Cohen Y, Haupt S, Haupt Y. (2005). Mdm2 in growth signaling and cancer. Growth Factors. 23, 183-92. Li, Q.H., Haga, I., Shimizu, T., Itoh, M., Kurosaki, T., and Fujisawa, J. (2002). Retardation of the G2–M phase progression on gene disruption of RNA binding protein Sam68 in the DT40 cell line. FEBS Lett. 525, 145–150. Li X, Wang J, Manley JL. (2005). Loss of splicing factor ASF/SF2 induces G2 cell cycle arrest and apoptosis, but inhibits internucleosomal DNA fragmentation. Genes Dev. 19, 2705-14. Li, X. and Manley, J.M. (2005). Inactivation of the SR protein splicing factor ASF/SF2 results in genomic instability. Cell 122, 365–378. Lo HW, Xia W, Wei Y, Ali-Seyed M, Huang SF, Hung MC. (2005). Novel prognostic value of nuclear epidermal growthfactor receptor in breast cancer. Cancer Res 65, 338–348. Maass N, Rosel F, Schem C, Hitomi J, Jonat W, Nagasaki K. (2002). Amplification of the BCAS2 gene at chromosome 1p13.3-21 in human primary breast cancer. Cancer Lett 185, 219-223. Mahajan KN, Mitchell BS (2003). Role of human Pso4 in mammalian DNA repair and association with terminal deoxynucleotidyl transferase. Proc Natl Acad Sci U S A. 100, 10746-51. Mantoni TS, Reid G, Garrett MD. (2006).Androgen receptor activity is inhibited in response to genotoxic agents in a p53-independent manner. Oncogene. 25, 3139-49. Marchenko ND, Wolff S, Erster S, Becker K, Moll UM. (2007). Monoubiquitylation promotes mitochondrial p53 translocation. EMBO J. 26, 923-34. McKean-Cowdin R, Kolonel LN, Press MF, Pike MC, Henderson BE. (2001). Germ-line HER-2 variant and breast cancer risk by stage of disease. Cancer Res 61, 8393-8394. Merlo GR, Siddiqui J, Cropp CS, Liscia DS, Lidereau R, Callahan R, Kufe DW. (1989).Frequent alteration of the DF3 tumor-associated antigen gene in primary human breast carcinomas. Cancer Res 49, 6966-6971. Mihara M, Erster S, Zaika A, Petrenko O, Chittenden T, Pancoska P, Moll UM. (2003). p53 has a direct apoptogenic role at the mitochondria. Mol Cell. 11, 577-90. Mitchell EL, Santibanez-Koref MF. (1990). 1p13 is the most frequently involved band in structural chromosomal rearrangements in human breast cancer. Genes Chromosomes Cancer 2, 278-289. Minn AJ, Kettlun CS, Liang H, Kelekar A, Vander Heiden MG, Chang BS, Fesik SW, Fill M, Thompson CB. (1999). Bcl-xL regulates apoptosis by heterodimerization-dependent and -independent mechanisms. EMBO J. 18, 632-43. Moll UM, Petrenko O. (2003).The MDM2-p53 interaction. Mol Cancer Res. 1, 1001-8. Review. Moll UM, Wolff S, Speidel D, Deppert W. (2005). Transcription-independent pro-apoptotic functions of p53. Curr Opin Cell Biol. 17, 631-6. Review. Montagna C, Andrechek ER, Padilla-Nash H, Muller WJ, Ried T. (2002). Centrosome abnormalities, recurring deletions of chromosome 4, and genomic amplification of HER2/neu define mouse mammary gland adenocarcinomas induced by mutant HER2/neu. Oncogene 21, 890-898 Momand J, Jung D, Wilczynski S, Niland J (1998). The MDM2 gene amplification database. Nucleic Acids Res 26, 3453– 3459 Mooney LM, Al-Sakkaf KA, Brown BL, Dobson PR. (2002). Apoptotic mechanisms in T47D and MCF-7 human breast cancer cells. Br J Cancer 87, 909-917. Munn KE, Walker RA, Varley JM. (1995). Frequent alterations of chromosome 1 in ductal carcinoma in situ of the breast. Oncogene 10, 1653-1657. Nagasaki K, Maass N, Manabe T, Hanzawa H, Tsukada T, Kikuchi K, Yamaguchi K. (1999). Identification of a novel gene, DAM1, amplified at chromosome 1p13.3-21 region in human breast cancer cell lines. Cancer Lett 140, 219-226. Neubauer G, King A, Rappsilber J, Calvio C, Watson M, Ajuh P, Sleeman J, Lamond A, Mann M. (1998). Mass spectrometry and EST-database searching allows characterization of the multi-protein spliceosome complex. Nat Genet 20, 5-6. O'Callaghan-Sunol C, Gabai VL, Sherman MY. (2007). Hsp27 modulates p53 signaling and suppresses cellular senescence. Cancer Res. 67, 11779-88 Qi C, Zhu YT, Chang J, Yeldandi AV, Rao MS, Zhu YJ. (2005). Potentiation of estrogen receptor transcriptional activity by breast cancer amplified sequence 2. Biochem Biophys Res Commun 328, 393-398. Riley T, Sontag E, Chen P, Levine A. (2008). Transcriptional control of human p53-regulated genes. Nat Rev Mol Cell Biol. 9, 402-12. Review. Russell, C.S., Ben-Yehuda, S., Dix, I., Kupiec, M., and Beggs, J.D. (2000). Functional analyses of interacting factors involved in both pre-mRNA splicing and cell cycle progression in Saccharomyces cerevisiae. RNA 6, 1565–1572. Schöndorf T, Scharl A, Kurbacher CM, Bien O, Becker M, Neumann R, Kolhagen H, Rustemeyer J, Mallmann P, Göhring UJ. (1999). Amplification of the mdr1-gene is uncommon in recurrent ovarian carcinomas. Cancer Lett 146, 195-199. Sharpless NE, DePinho RA. (2002). p53: good cop/bad cop. Cell. 110, 9-12. Shenk JL, Fisher CJ, Chen SY, Zhou XF, Tillman K, Shemshedini L. (2001). p53 represses androgen-induced transactivation of prostate-specific antigen by disrupting hAR amino- to carboxyl-terminal interaction. J Biol Chem. 276, 38472-9 Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. 1987. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 235, 177-82. Smits, V.A. and Medema, R.H. (2001). Checking out the G(2)/M transition. Biochim. Biophys. Acta 1519, 1–12. Sun C, Shi Y, Xu LL, Nageswararao C, Davis LD, Segawa T, Dobi A, McLeod DG, Srivastava S. (2006). Androgen receptor mutation (T877A) promotes prostate cancer cell growth and cell survival. Oncogene. 25, 3905-13. Suzuki H, Ueda T, Ichikawa T, Ito H. (2003). Androgen receptor involvement in the progression of prostate cancer. Endocr Relat Cancer. 10, 209-16. Toledo F, Wahl GM. (2006). Regulating the p53 pathway: in vitro hypotheses, in vivo veritas. Nat Rev Cancer. 6, 909-23. Tsai TC, Lee YL, Hsiao WC, Tsao YP, Chen SL. (2005). NRIP, a novel nuclear receptor interaction protein, enhances the transcriptional activity of nuclear receptors. J Biol Chem 280, 20000-20009. Tsao YP, Huang, SJ, Chang, JL, Hsieh, JT, Pong, RC, Chen, SL. (1999). Adenovirus-mediated p21(WAF1/SDII/CIP1) gene transfer induces apoptosis of human cervical cancer cell lines. J Virol 73, 4983-4990. Vousden KH. (2000). p53: death star. Cell 103, 691-694. Vousden KH, Prives C. (2005). P53 and prognosis: new insights and further complexity. Cell. 120, 7-10. Wang W, El-Deiry WS. (2008). Restoration of p53 to limit tumor growth. Curr Opin Oncol. 20, 90-6. Watson IR, Irwin MS. (2006). Ubiquitin and ubiquitin-like modifications of the p53 family. Neoplasia. 8, 655-66. Wolff S, Erster S, Palacios G, Moll UM. (2008). p53's mitochondrial translocation and MOMP action is independent of Puma and Bax and severely disrupts mitochondrial membrane integrity. Cell Res. 2008 May 27. Worsham MJ, Pals G, Schouten JP, Miller F, Tiwari N, van Spaendonk R, Wolman SR. (2006). High-resolution mapping of molecular events associated with immortalization, transformation, and progression to breast cancer in the MCF10 model. Breast Cancer Res Treat 96, 177-86. Wigler, M., Pellicer, A., Silverstein, S., and Axel, R. (1978). Biochemical transfer of single-copy eukaryotic genes using total cellular DNA as donor. Cell 14:725. Yang Y, Li CC, Weissman AM. (2004). Regulating the p53 system through ubiquitination. Oncogene. 23, 2096-106. Review. Yu D, Hung MC. (2000). Overexpression of ErbB2 in cancer and ErbB2-targeting strategies. Oncogene 19, 6115-6121. Zhang N, Kaur R, Lu X, Shen X, Li L, Legerski RJ. (2005). The Pso4 mRNA splicing and DNA repair complex interacts with WRN for processing of DNA interstrand cross-links. J Biol Chem. 280, 40559-67 | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/26772 | - |
dc.description.abstract | 一個新穎的細胞核蛋白BCAS2(breast cancer amplified sequence 2),本實驗室利用雄性激素受體(androgen receptor, AR)當成餌,於人類HeLa MATCHMAKER cDNA基因庫中,利用yeast-two hybrid選殖系統所鑑定出來;目前的文獻顯示,BCAS2基因座落在第一號染色體1p13.3-21區域,並且在部分乳癌細胞株及檢體中具有基因增殖(gene amplification)的現象,並且BCAS2可增強雌激素受體(estrogen receptor, ER)所誘導的基因表現及可能參與在前細胞凋亡的過程中。
在本研究中,為了分析及鑑定BCAS2蛋白質的功能,使用了GST-Pull down的技術,藉由與MCF-7核萃取物共同作用,我們實驗室首次發現BCAS2與抑癌基因p53於細胞核中具有交互作用;此外,利用transiently transfection大量表現BCAS2,則會抑制p53的活性且使得p53下游基因p21表現量減少;相反的,利用RNAi技術均可knock down不論是內生或外送的BCAS2,並導致p21和BAX基因表現量上升,並更進一步減緩MCF-7及LNCaP細胞(野生型 p53)的細胞生長並增加死亡的比例,但在不具有p53的細胞株H1299中則無此效果;此外在MCF-7細胞中,處理DNA damage藥物adriamycin活化p53所引起的現象,可藉由BCAS2大量表現加以回復;因此經由以上結果推測,BCAS2可能當成p53的負調控者的角色。 此外,BCAS2曾被報導在ligand存在下,可增加雌激素受體媒介的基因轉錄作用;而在我們的研究中,BCAS2亦可與AR相互作用並增強其媒介的基因轉錄作用,且增加攝護腺癌中生化標記的PSA(prostate specific antigen)表現量,因此證明在prostate cancer細胞中,BCAS2亦可當成AR的一個轉錄輔因子,增強AR媒介的基因轉錄作用。在此研究中,我們目前已鑑定出BCAS2的雙重功能:一為核接受體的coactivator,另一個角色則為p53的負調控者。 | zh_TW |
dc.description.abstract | A nuclear protein which is encoded by a novel gene, breast cancer amplified sequence 2 (BCAS2), has been identified by applying the androgen receptor (AR) as a bait to prey a human HeLa MATCHMAKER cDNA library in a yeast-two hybrid screening system. Recent reports from the other groups show that BCAS2 is mapped on the chromosome 1p13.3-21 region, and also can enhance estrogen receptor (ER)-mediated transcription activity and regulate pro-apoptotic activity.
In this study, for characterization and identification of the functions of BCAS2, the GST pull-down assay was conducted to analyze the BCAS2 interacting proteins from nuclear extracts. Here, we first demonstrated that BCAS2 can directly interact with p53 in nucleus by in vitro GST pull-down assay, and the reciprocal IP-Western. Additionally, BCAS2 overexpression can lead to repress the activities of p53 by p21 promoter reporter assay, and can block p53-inducible p21 protein expression when treated with doxorubicin. When silencing of BCAS2 by siRNA, it can enhance the p53 transcriptional activities resulting in the increase of p21 and BAX protein expression, and also can cause the decrease of cell growth and increase cell death both in MCF-7 and LNCaP cells those containing wild type p53. It suggests that BCAS2 may play a role as a negative regulator of p53. On the other hand, in our investigation BCAS2 also can bind to androgen receptor and can enhance AR-driven prostate specific antigen (PSA) promoter activity which is a biomarker to monitor prostate cancer. The reporter assay and RT-PCR results revealed that the decrease of endogenous BCAS2 expression caused by siBCAS2 decreased the AR-mediated PSA promoter activity and PSA mRNA expression in LNCaP cells. Additionally AR and BCAS2 can co-localize on the AR response elements within PSA promoter by the chromatin IP assay. BCAS2 is also as a transcription cofactor to enhance AR-mediated gene expression in prostate cancer cells. In this study, we demonstrate that BCAS2 has dual roles: one is a coactivator of the nuclear receptor and the other the inhibitor of p53. | en |
dc.description.provenance | Made available in DSpace on 2021-06-08T07:24:55Z (GMT). No. of bitstreams: 1 ntu-97-R95445126-1.pdf: 1423835 bytes, checksum: c436a696f428b8c273facfd2c89d6eb5 (MD5) Previous issue date: 2008 | en |
dc.description.tableofcontents | 口試委員會審定書
誌謝 中文摘要 ABSTRACT CHAPTER 1.INTRODUCTION..............................................................................1 1.1The BCAS2 Discovery…………………………………………1 1.2The characteristic of BCAS2 ………………………….……….2 1.3BCAS2 in clinical significance....…………………...…………5 1.4Aim of this study……………………………………………….6 2MATERIALS AND METHODS………………………………………………7 2.1Plasmids……………………………………………………………7 2.2Antibodies …………………………………………………………9 2.3Cell Culture………………………………………………………9 2.4Transfection………………………………………………………10 2.5GST fusion proteins and pull-down assay……………………12 2.6Nuclear/Cytoplasm Fraction…………………………………..13 2.7In vitro transcription/translation and pull-down analysis……..14 2.8Design and Construction of siRNA…………………………...15 2.9Fluorescence and Immunofluorescence microscopy………….17 2.10Co-immunoprecipitation and Western Blot Analysis………18 2.11Luciferase Activity Assays…………………………………19 2.12Cell Cycle Analysis……………………………………………20 2.13Cell proliferation assay………………………………………20 2.14Chromatin Immunoprecipitation Assay………………………21 2.15RNA extraction and Reverse Transcription-PCR……………23 3RESULTS …………………………………………………………25 3.1BCAS2 can interact with p53 in vitro and in vivo………25 3.2BCAS2 can inhibit the activity of tumor suppressor p53 in a dose-dependent manner………………………………………27 3.3Identification of siRNA to BCAS2……………………………30 3.4Silencing of BCAS2 expression can induce cell death……31 3.5BCAS2 inhibits p53 binding to the p53-response elements…34 3.6BCAS2 can interact with androgen receptor in vivo…………36 3.7BCAS2 can enhance AR-mediated PSA promoter activity……37 3.8BCAS2 co-localizes with AR in PSA promoter………………40 4DISCUSSION…………………………………………………………41 Part one………………………………………………………………41 Part two………………………………………………………………47 5CONCLUSION…………………………………………………………50 REFERENCES……………………………………………………………52 FIGURES………………………………………………………………61 APPENDIX………………………………………………………………83 | |
dc.language.iso | en | |
dc.title | BCAS2的雙重功能之研究:為抑癌基因p53的新穎負調控者及核接受體的共同轉錄因子 | zh_TW |
dc.title | The Dual Roles of BCAS2 as a Novel Negative Regulator of the p53 Tumor Suppressor and a Transcription Cofactor of Nuclear Receptor | en |
dc.type | Thesis | |
dc.date.schoolyear | 96-2 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 鄧述諄(Shu-Chun Teng),董馨蓮(Shin-Lian Doong),謝小燕(Sheau-Yann Shieh) | |
dc.subject.keyword | p53負調控者,BCAS2,雄激素受體,細胞凋亡,p21, | zh_TW |
dc.subject.keyword | p53 negative regulator,BCAS2,androgen receptor,apoptosis,p21,transcription cofactor, | en |
dc.relation.page | 93 | |
dc.rights.note | 未授權 | |
dc.date.accepted | 2008-07-17 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 微生物學研究所 | zh_TW |
顯示於系所單位: | 微生物學科所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-97-1.pdf 目前未授權公開取用 | 1.39 MB | Adobe PDF |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。